Go to Contents Go to Navigation

Handok Pharmaceutical, Genexine purchase U.S. bio firm

All News 14:17 January 08, 2019

SEOUL, Jan. 8 (Yonhap) -- South Korean drugmaker Handok Pharmaceuticals Co. said Tuesday that it has entered a US$25 million preferred stock purchase agreement with local player Genexine Inc. to invest in an American drugmaker.

The arrangement allows the two companies to purchase a combined 54 percent share of Rezolute Inc., a clinical stage biopharmaceutical company, officials said.

Handok Pharmaceutical said the purchase is a strategic investment as the company aims to make further inroads into the world's largest biopharmaceutical market.

"We believe the purchase will play a bigger role for Handok to make headway in the United States," CEO Kim Young-jin said in a press release.

Rezolute, established in 2010, specializes in the development of medication to fight metabolic and orphan diseases.

Handok Pharmaceuticals' corporate logo (Yonhap)


Send Feedback
How can we improve?
Thanks for your feedback!